INTRODUCTION
NSCLC, death, lung cancer, deaths, PD‐L1
LUNG CANCER, NSCLC
Globally, lung cancer was the leading cause of cancer‐related mortality in 2020, contributing to approximately 1.8 million deaths.Notably, the results of clinical trials of immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors, indicate that they are expected to significantly improve overall survival (OS) despite a lower objective response rate (ORR).Commonly used anticancer agents for previously treated patients with advanced NSCLC include docetaxel, pemetrexed, gemcitabine, and a combination of docetaxel and ramucirumab. However, nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) has recently demonstrated significantly longer progression‐free survival (PFS) than docetaxelSeveral chemotherapy and PD‐1 or PD‐L1 [PD‐(L)1] inhibitor combination regimens are currently available for patients with advanced NSCLC. Among these, the combination of nab‐paclitaxel and carboplatin with a PD‐(L)1 inhibitor has been reported to be both effective and well tolerated.